This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Swain, R. Articles by Thombre, D.P. Search for Related Content PubMed Articles by Swain, R. Articles by Thombre, D.P. Social Bookmarking                         What's this?

A Study on the Neurotoxicity of Broxyquinoline and Brobenzoxaldine Combination in Therapeutic Doses

Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605006, India

J.S. Bapna

Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605006, India

A.K. Das

Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605006, India

S. Chandrasekar

Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605006, India

R.P. Swaminathan

Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605006, India

B. Bosco

Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605006, India

S. Veliath

Department of Physiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605006, India

D.P. Thombre

Department of Physiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605006, India

1 The neurotoxicity of a combination of broxyquinoline and brobenzoxaldine (Intestopan Forte, containing 500 mg and 100 mg of the drugs respectively per capsule) was investigated by prospective clinical and electrophysiological studies in patients and volunteer subjects given the drugs in therapeutic doses (two capsules three times a day for 5 days).

2 Of 16 patients with intestinal amoebiasis given the drugs (study A), 13 (81.25%) were cured. Adverse effects were mild and did not affect treatment. No neurological adverse effect was reported. Neurological examinations revealed no abnormality in any patient after treatment.

3 Seven volunteer subjects underwent medical, neurological and ophthalmological examinations, and electrophysiological studies of ulnar and peroneal nerve conduction before and after treatment with the drugs in therapeutic doses (study B). Transient parasthesiae were reported by one subject on the fourth day of treatment. No medical, neurological or ophthalmological abnormality was detected in any subject after treatment. There was no significant change in motor nerve conduction velocities. There was a significant (P<0.001) increase in the stimulus strength for distal ulnar stimulation and a significant (P<0.01) decrease in stimulus duration for proximal and distal ulnar stimulation. No significant changes were seen in the peroneal nerves in these parameters. No qualitative abnormality was seen in the oscilloscopic patterns of nerve conduction after treatment. 4 Literature on the neurotoxicity of the halogenated hydroxyquinolines is reviewed.

5 It is concluded that broxyquinoline and brobenzoxaldine (and probably other halogenated hydroxyquinolines as well) are safe and effective in therapeutic doses; neurotoxicity is unlikely to occur when these drugs are used according to therapeutic recommendations.

Human & Experimental Toxicology, Vol. 5, No. 1, 35-41 (1986)
DOI: 10.1177/096032718600500107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?